Imagin Medical Inc. IMEXF Archives - Page 5 of 6

WednesdayFeb 10, 2021 3:03 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Anticipates ‘Breakout Year’ in 2021

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, expects to achieve important milestones in the year ahead. The company’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’ ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. The system’s key feature is its adaptability to almost any scope already in use by hospitals and surgical centers. Despite the challenges of 2020, Imagin was able to transition its product from the development stage to manufacturing, contracting with FDA registered and ISO 13485:2016-certified manufacturer Lighthouse Imaging.…

FridayFeb 05, 2021 1:42 pm

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Proprietary System Could Help Reduce Bladder Cancer Recurrence

The current standard for bladder cancer visualization, white light, is over three decades old and used in 95% of the bladder cancer surgeries The recurrence rate of bladder cancer is more than 50% due to the inability to see clear margins in the white light surgical standard for visualization Imagin Medical Inc.’s proprietary i/Blue(TM) System changes the way that surgeons visualize bladder cancer with side-by-side imaging of white and blue light pictures on one screen Blue light procedures are capable of reducing recurrence rates by 12-43% depending on the type, stage, and grade of bladder cancer The global bladder cancer…

ThursdayFeb 04, 2021 1:12 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Harnesses Blue Light, Innovative Technology for Cancer Imaging

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is harnessing the virtues of blue light in a health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and develop the appropriate response strategy. Imagin is developing its platform for use in bladder cancer surgery. It relies on Cysview, a drug that rapidly infiltrates cancer cells and causes them to glow bright pink under blue light. Cysview is administered just before surgery and the blue light is used endoscopically to locate and examine…

WednesdayFeb 03, 2021 2:01 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology Set to Revolutionize Bladder Cancer Visualization

The established and most prominent method of visualizing bladder cancer, white light, lacks the clarity needed to detect finer margins of tumors, which increases the likelihood of recurrence The more recent, improved method, blue light, provides clarity yet introduces cost barriers to adoption Imagin Medical’s i/Blue Imaging(TM) System combines the best of both methods, clarity and real-time visualization at a lower cost The system is highly adaptable to current endoscopic instruments, making it easy and affordable to implement For over 30 years, the standard of visualizing bladder cancer during surgery has been white light illumination through an endoscopic procedure called…

FridayJan 29, 2021 12:12 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Contracts Torrey Hills Capital to Boost Awareness of Its Proprietary Cancer Visualization Technology

Torrey Hills Capital is a leading investor and financial public relations firm that offers extensive expertise in investor relations, corporate communications and other market support operations The services provided to Imagin Medical will be overseen by Torrey Hills Founder and Principal Cliff Mastricola Imagin believes its proprietary imaging technology, the i/Blue Imaging System(TM), will establish a new standard of care in visualizing cancer during minimally invasive procedures Company’s current focus is bladder cancer, the 6th most prevalent form of cancer and most expensive to treat Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has engaged the services of…

TuesdayJan 26, 2021 2:11 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Enters 2021 with Optimism for Its Cancer Imaging Technology

Imagin Medical Inc. successfully weathered the 2020 pandemic-induced economic challenges and transitioned its surgical visualization product, the i/Blue Imaging System(TM) from the development stage to manufacturing and has after Imagin’s next stage will be supported by a $3 million convertible note, with the final funding tranche expected to close this quarter The i/Blue Imaging System combines the advantages of blue light with advanced optic and light sensors to address the limitations of both white and blue light imaging to help surgeons better visualize and remove cancerous cells. The system uses a contrast agent to highlight the cancer and projects both…

WednesdayJan 20, 2021 10:20 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital") to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange ("CSE"). The move enables the company to cultivate an informed investor audience in both the U.S. and Canadian marketplaces. The company has engaged the firm at a rate of US$7,000 per month. Following the initial term…

FridayJan 15, 2021 10:01 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Offers Significant Advantages Over Current Standard Of Visualizing Bladder Cancer During Surgery

The number of bladder cancer cases in 2020 is estimated at 81,400, nearly 4.5% of all newly diagnosed cancer cases, and the current bladder cancer research market is projected to grow at a CAGR of 4.03% through 2026 White light, the most widely accepted current standard of care for bladder cancer removal, may not be the best option in helping to prevent recurrence, leaving hundreds of thousands of patients afraid of relapse Blue light has been introduced and proven to detect 25% more tumors, but because of limitations, has not been widely accepted Imagin Medical’s i/Blue Imaging System(TM) can be…

WednesdayJan 13, 2021 11:02 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Engages IBN, Builds Momentum for 2021

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Imagin Medical. Like most companies during 2020, Imagin had to adapt to the unexpected circumstances surrounding…

TuesdayJan 12, 2021 12:02 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Visualizes a World with Superior Bladder Cancer Surgical Procedures

Surgical imaging company Imagin Medical Inc. has developed a proprietary technology that enhances surgeons’ efforts to identify the full extent of bladder cancers and remove them Imagin’s i/Blue Imaging (TM) System uses blue light in combination with a fluorescent contrasting agent that highlights the tumor on an endoscope’s camera display to help surgeons remove the cancerous cells more completely than the white light standard Bladder cancer is the fourth most common cancer in men and the second most common genitourinary cancer The American Cancer Society forecasts that, during this year, about 81,400 new cases of bladder cancer would be reported…

Site Search

Company Search

Tag: Imagin Medical Inc. IMEXF